329PD - Survival of patients with synchronous and metachronous breast cancer and meningioma

Date 08 October 2016
Event ESMO 2016 Congress
Session CNS tumours
Topics Breast Cancer
Central Nervous System Malignancies
Presenter Catarina Ribeiro
Citation Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367
Authors C.G. Ribeiro1, L. Mascarenhas2, J.P. Lavrador3, A. Peralta4, M. Valente5
  • 1Dept. Of Oncology, Centro Hospitalar Lisboa Central-CHLC-Hospital São Jose, 1169-050 - Lisboa/PT
  • 2Pathology, Centro Hospitalar Lisboa Central-CHLC-Hospital São Jose, 1169-050 - Lisboa/PT
  • 3Neurosurgery, Centro Hospitalar Lisboa Norte - Hospital Sta Maria (HSM-CHLN), 1169-050 - Lisboa/PT
  • 4Public Health, Public Health, 1000 - Lisboa/PT
  • 5Pediatrics, John Radcliffe Hospital University of Oxford, OX3 9DU - Oxford/GB



The prognostic relevance of the association between Breast Cancer (BC) and Meningioma (M) is still unknown. Therefore, our aim was to evaluate the survival impact of tumor exposure sequence - synchronous or metachronous - in patients with these tumors.


Patients were divided in three groups according to the exposure

variable – sequence of tumors: M before BC (M → BC), synchronous BC and M (BC + M) and BC before M (BC → M). Only patients exclusively with both these tumors were included. The SEER database was used. Demographic variables, meningioma variables (site, grade and treatment) and breast cancer variables (grade, stage, hormonal receptor status and treatment) were collected and the primary outcome was oncological survival.


A total of 1715 patients were followed for a median follow-up of 84 months. The BC + M group had the shortest survival (median of 32 months) and BC → M the longest (median of 110 months). The unadjusted analysis revealed BC + M group as statistically related to the shortest survival (HR 3.13, 95%[CI] [1.62-6.04]). The adjusted analysis confirmed that the BC + M group as the one with worst prognosis (HR 3.11, 95%[CI] [1.58-6.19]), with no statistical difference between the metachronous tumors . Increasing age (HR:1.13, 95%CI: 1.11-1.15, p  0.05) but have no influence on metachronous tumors survival (p 


Synchronous BC and M were associated with lower survival, when compared with metachronous tumors. Increasing age had a negative influence on patients' survival. Grade III meningioma and hormonal receptor status only influenced synchronous tumors oncological survival.

Clinical trial identification

Legal entity responsible for the study

Clinical Scholars Research Training Program, Harvard Medical School Portugal




All authors have declared no conflicts of interest.